2-6 years: IV 8-10 mg/kg/DAY given as a single daily dose
≥6 years to <12 years: IV 7 mg/kg/DAY given as a single daily dose
≥12 years: IV 4-6 mg/kg/DAY given as a single daily dose
Very limited data available.
PMA ≥32 weeks: IV 12mg/kg/DAY divided q12h
Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.
Not routinely used as first-line therapy.
The manufacturer recommends avoiding use in patients <12 months due to musculoskeletal, neuromuscular, and nervous system adverse effects observed in neonatal canine models.
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection
Creatine kinase weekly, renal function
Myopathy including rhabdomyolysis
GI side effects common
Statins and fibrates: Monitor creatine kinase or hold while on daptomycin therapy (increased myopathy)
Recommend Infectious Disease Consult
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection
Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane
Average serum half life:
Neonates and Infants <3 months: 6.2 hours
Children: 5 to 7 hours
Route of Elimination: 78% of the dose excreted in urine as unchanged drug; feces (6%)